PS-002 for the Treatment of IgA Nephropathy in Adults

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1/PHASE2

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-11-30

Study Completion Date

2029-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to evaluate safety, tolerability, and preliminary effectiveness following administration of PS-002 in adults with primary Immunoglobulin A (IgA) nephropathy. This will be a first-in-human study and will include participants at high risk of disease progression despite receiving current standard-of-care treatment.

Participants will be monitored for up to one year after receiving PS-002 and invited to take part in a long-term follow-up study (total follow-up: 5 years).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA Nephropathy

NCT07305974

IgA Nephropathy (IgAN)

RECRUITING PHASE2

Efficacy and Safety of SM101 in the Treatment of IgA Nephropathy

NCT02605525

Immunoglobulin A Nephropathy

WITHDRAWN PHASE2

Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN)

NCT06454110

IgA Nephropathy

NOT_YET_RECRUITING PHASE2

Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN)

NCT06687174

IgA Nephropathy (IgAN)

NOT_YET_RECRUITING PHASE2

A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

NCT06935357

Immunoglobulin A Nephropathy (IgAN)

RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Immunoglobulin A (IgA) Nephropathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SEQUENTIAL

Part 1: In the dose exploration of the study, 3 different ascending dose levels will be administered using a sentinel dosing strategy Part 2: Participants will receive the optimal biological dose identified in Part 1 of the study

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PS-002

Part 1: Dose escalation in three groups: Group 1: Low dose, Group 2: Intermediate Dose, Group 3: High Dose.

Part 2: Dose expansion in a fourth group with a selected dose.

Group Type EXPERIMENTAL

PS-002

Intervention Type GENETIC

Adeno-associated viral vector containing the human Complement Factor I (CFI) gene

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PS-002

Adeno-associated viral vector containing the human Complement Factor I (CFI) gene

Intervention Type GENETIC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of primary IgA nephropathy (IgAN) as evidenced by renal biopsy.
* A historic kidney biopsy performed within 36 months prior to screening with reported evidence of complement component 3 (C3) deposition. If the participant had a kidney biopsy performed over 36 months prior to Screening, a new kidney biopsy should be carried out during the Screening period. This biopsy must exhibit signs of ongoing complement system activity.
* Proteinuria as assessed at the Screening visit by UPCR at least 1g/g (at least 1000 mg/g) OR total protein excretion at least 1 g/24 h (at least 1000 mg/24h) sampled from 24 h urine collection.
* eGFR calculated using the CKD-EPI formula at least 45 mL/min/1.73m\^2.
* Sitting office systolic blood pressure equal to or less than 140 mmHg, diastolic blood pressure equal to or less than 90 mmHg.
* All participants must have been on best supportive care for IgAN, as per region-specific requirements defined in the protocol.

Exclusion Criteria

* A participant has nephrotic syndrome, defined for this purpose as 24 h urine protein greater than 3.5g with concurrent hypoalbuminemia (serum albumin less than 3.0 g/dL \[less than 30 g/L\]).
* Any secondary IgAN defined as associated with gastrointestinal and liver disorders (liver cirrhosis, celiac disease, Crohn's disease, ulcerative colitis), autoimmune disorders (dermatitis herpetiformis, psoriasis, seronegative arthritis, systemic lupus erythematosus, rheumatoid arthritis), malignancy (IgA myeloma, lymphoma, lung cancer, renal cell cancer, cutaneous T-cell lymphoma), respiratory disorders (bronchiolitis obliterans, idiopathic pulmonary fibrosis) etc.
* Having a major concurrent non-IgAN-related disease that, in the opinion of the investigator, prevents the assessment of IgAN.
* History of malignancy; or bone marrow or organ transplant.
* History of, or currently active primary or secondary immunodeficiency, including known history of human immunodeficiency virus infection, and other severe immunodeficiency blood disorders.
* Presence of other significant medical conditions that would create an unacceptable procedure or anesthesia risk.
* Aspartate aminotransferase or alanine aminotransferase greater than 1.5 times the upper limit of normal.
* History of serious infection requiring parenteral antibiotics within the past 8 weeks prior to study drug administration.
* Participants previously treated with immunosuppressive/immunomodulatory agents such as, but not limited to, cyclophosphamide, infliximab, complement inhibitor, canakinumab, mycophenolate mofetil, mycophenolate sodium, cyclosporine, tacrolimus, everolimus, or systemic corticosteroids (exposure greater than 7.5mg/day prednisone/prednisolone equivalent) within 90 days (or 180 days for rituximab) prior to Screening. Participants previously or currently receiving oral budesonide (Kinpeygo/Tarpeyo) require wash out for 90 days prior to the study drug administration.
* Exposed to a live or attenuated vaccine within the 6 weeks prior to study drug administration.
* Participants with a known sensitivity or intolerance to corticosteroid therapy.
* Known hypersensitivity to study drug ingredients.
* Prior treatment with PS-002 or any other gene therapy, or participation in any other investigational trial during this study.
* Positive serology for hepatitis B or C, i.e., positive hepatitis B surface antigen or hepatitis C ribonucleic acid (RNA) viral load positive.
* Participants treated with potentially hepatotoxic medications unless they have been monitored in accordance with the drug label and have received a stable dose since \>90 days prior to dosing without clinically significant liver enzyme fluctuations.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.